Active substances
Adapalene + Benzoyl peroxide
- SFDA 5
- US FDA 14
- Health Canada 6
- US price lines 1
- NHS prices 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Adzoy | 0.3,2.5 %,% | Gel · Topical | 1 Tube | SAR 76.80 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| Adzoy | 0.1,2.5 %,% | Gel · Topical | 1 Tube | SAR 25.55 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| Deriva BPO | 25,1 mg,mg | Gel · Topical | 1 Tube | SAR 40.30 | Generic · Prescription | Glenmark Pharmaceuticals Limited | Valid |
| Epiduo Forte | 2.5,0.3 %,% | Gel · Topical | 1 Multidose container | SAR 76.80 | NCE · Prescription | GALDERMA | Valid |
| EPIDUO 1.25% GEL | 25,1 mg,mg | Gel · Topical | 1 Tube | SAR 28.80 | NCE · Prescription | GALDERMA | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| EPIDUO FORTE | 0.3%;2.5% | gel · topical | GALDERMA LABS | Prescription | 15 Jul 2015 |
| ADAPALENE AND BENZOYL PEROXIDE | 0.1%;2.5% | gel · topical | PADAGIS ISRAEL | Prescription | 23 Jan 2018 |
| ADAPALENE AND BENZOYL PEROXIDE | 0.1%;2.5% | gel · topical | SUN PHARMA CANADA | Prescription | 24 Jan 2018 |
| ADAPALENE AND BENZOYL PEROXIDE | 0.1%;2.5% | gel · topical | ENCUBE | Prescription | 23 May 2018 |
| ADAPALENE AND BENZOYL PEROXIDE | 0.3%;2.5% | gel · topical | SUN PHARMA CANADA | Prescription | 17 Oct 2018 |
| ADAPALENE AND BENZOYL PEROXIDE | 0.1%;2.5% | gel · topical | GLENMARK PHARMS LTD | Prescription | 8 Nov 2019 |
| ADAPALENE AND BENZOYL PEROXIDE | 0.3%;2.5% | gel · topical | PADAGIS ISRAEL | Prescription | 31 May 2022 |
| ADAPALENE AND BENZOYL PEROXIDE | 0.3%;2.5% | gel · topical | ZYDUS PHARMS | Prescription | 3 Jun 2022 |
| ADAPALENE AND BENZOYL PEROXIDE | 0.3%;2.5% | gel · topical | ACTAVIS LABS UT INC | Prescription | 22 Jun 2022 |
| ADAPALENE AND BENZOYL PEROXIDE | 0.3%;2.5% | gel · topical | ALEMBIC | Prescription | 4 Aug 2022 |
| DIFFERIN EPIDUO | 0.1%;2.5% | gel · topical | GALDERMA LABS LP | Over-the-counter | 22 May 2026 |
| ADAPALENE AND BENZOYL PEROXIDE | 0.3%;2.5% | gel · topical | AUROBINDO PHARMA LTD | Prescription | 22 Jul 2026 |
| EPIDUO | 0.1%;2.5% | gel · topical | GALDERMA LABS LP | Discontinued | 8 Dec 2008 |
| ADAPALENE AND BENZOYL PEROXIDE | 0.1%;2.5% | gel · topical | ACTAVIS MID ATLANTIC | Discontinued | 30 Sep 2015 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| SANDOZ ADAPALENE / BENZOYL PEROXIDE | 02489007 | 2.5 % / W/W; 0.1 % / W/W | GEL · TOPICAL | SANDOZ CANADA INCORPORATED |
| SANDOZ ADAPALENE / BENZOYL PEROXIDE FORTE | 02517205 | 2.5 % / W/W; 0.3 % / W/W | GEL · TOPICAL | SANDOZ CANADA INCORPORATED |
| TACTUPUMP | 02365871 | 2.5 % / W/W; 0.1 % / W/W | GEL · TOPICAL | GALDERMA CANADA INC. |
| TACTUPUMP FORTE | 02446235 | 0.3 % / W/W; 2.5 % / W/W | GEL · TOPICAL | GALDERMA CANADA INC. |
| TARO-ADAPALENE/BENZOYL PEROXIDE | 02456923 | 2.5 % / W/W; 0.1 % / W/W | GEL · TOPICAL | TARO PHARMACEUTICALS INC |
| TARO-ADAPALENE/BENZOYL PEROXIDE FORTE | 02505053 | 0.3 % / W/W; 2.5 % / W/W | GEL · TOPICAL | TARO PHARMACEUTICALS INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | EPIDUO FORTE 0.3-2.5% GEL PUMP | $14.9672 | per GM | 23 Sep 2026 |
| NHS Drug Tariff | Adapalene 0.1% / Benzoyl peroxide 2.5% gel | £20.85 | 45 gram | 1 Oct 2026 |
| NHS Drug Tariff | Adapalene 0.1% / Benzoyl peroxide 2.5% gel | £27.80 | 60 gram | 1 Oct 2026 |
| NHS Drug Tariff | Adapalene 0.3% / Benzoyl peroxide 2.5% gel | £27.80 | 60 gram | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.